Literature DB >> 6145497

A study of possible excitatory effects of N-acetylaspartylglutamate in different in vivo and in vitro brain preparations.

N Riveros, F Orrego.   

Abstract

The possible excitatory effect of N-acetyl-alpha- aspartylglutamate ( NAAG ) was studied in 3 different systems. First on the increase in 45Ca2+ influx into rat brain cortex slices in vitro, a process that is enhanced by excitatory substances. In this system 1.25 mM NAAG was entirely inactive, nor did it potentiate the excitatory effect of 0.5 mM L-glutamate. NAAG (1 mM) was able to inhibit the specific binding of [3H]kainic acid to its receptors in rat brain cortex membranes by 57.2%, but such inhibition could be accounted by the release of L-glutamate because of hydrolysis of NAAG during the incubation. In vivo infusion of NAAG (10 or 100 micrograms) through permanently implanted cannulas into the cat dorsal hippocampus, or into the pulvinar nucleus of the thalamus, was also without effect. NAAG was also unable to potentiate or to antagonize the excitatory effects of glutamate in this preparation.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6145497     DOI: 10.1016/0006-8993(84)90727-3

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  8 in total

1.  N-Acetyl-aspartylglutamate (NAAG) in human cerebrospinal fluid: Determination by high performance liquid chromatography, and influence of biological variables.

Authors:  V Brovia; A Ricciardi; L Barbeito
Journal:  Amino Acids       Date:  1995-06       Impact factor: 3.520

Review 2.  Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer.

Authors:  C Bařinka; C Rojas; B Slusher; M Pomper
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

Review 3.  Advances in understanding the peptide neurotransmitter NAAG and appearance of a new member of the NAAG neuropeptide family.

Authors:  Joseph H Neale; Rafal T Olszewski; Daiying Zuo; Karolina J Janczura; Caterina P Profaci; Kaleen M Lavin; John C Madore; Tomasz Bzdega
Journal:  J Neurochem       Date:  2011-07-01       Impact factor: 5.372

Review 4.  The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease.

Authors:  James C Evans; Meenakshi Malhotra; John F Cryan; Caitriona M O'Driscoll
Journal:  Br J Pharmacol       Date:  2016-09-23       Impact factor: 8.739

5.  GCP II (NAALADase) inhibition suppresses mossy fiber-CA3 synaptic neurotransmission by a presynaptic mechanism.

Authors:  Emilio R Garrido Sanabria; Krystyna M Wozniak; Barbara S Slusher; Asaf Keller
Journal:  J Neurophysiol       Date:  2003-08-13       Impact factor: 2.714

6.  Glutamate carboxypeptidase inhibition reduces the severity of chemotherapy-induced peripheral neurotoxicity in rat.

Authors:  Valentina A Carozzi; Alessia Chiorazzi; Annalisa Canta; Rena G Lapidus; Barbara S Slusher; Krystyna M Wozniak; Guido Cavaletti
Journal:  Neurotox Res       Date:  2009-09-15       Impact factor: 3.911

7.  Dysregulation of glutamate carboxypeptidase II in psychiatric disease.

Authors:  Tomás R Guilarte; Dima A Hammoud; Jennifer L McGlothan; Brian S Caffo; Catherine A Foss; Alan P Kozikowski; Martin G Pomper
Journal:  Schizophr Res       Date:  2008-01-10       Impact factor: 4.939

8.  Group II metabotropic glutamate receptors inhibit glutamate release at thalamocortical synapses in the developing somatosensory cortex.

Authors:  Z Mateo; J T Porter
Journal:  Neuroscience       Date:  2007-04-06       Impact factor: 3.590

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.